[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MRC\u002FUVRI and LSHTM Uganda Research Unit\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100613351","a-family-centred-approach-enhancing-cardiovascular-health-in-ugandan-adolescents-and-their-families-100613351",false,"NCT07265453","A Family-centred Approach Enhancing Cardiovascular Health in Ugandan Adolescents and Their Families","A Family Centred Approach to Enhance Lifestyle Change and Behavioural Modification for Prevention of Cardiovascular Diseases Among Adolescents and Their Families in Uganda","FaCe-D","Inclusion Criteria:\n\n* Aged 10 -19 years\n* Household head\u002Fparent has provided consent\u002Fpermission\n* Planning to continue staying in the study village for the next 12 months\n\nExclusion Criteria:\n\n* In a boarding school or planning to join a boarding school\n* Pregnant or lactating\n* Known to have a chronic condition such as mental illness\n* The adolescent does not assent or consent",true,"ALL","10 Years","19 Years",{"count":22,"type":23},1280,"ESTIMATED","INTERVENTIONAL",[26],"NA","The FaCe-D Study, with funding from the Canadian Institute for Health Research (CIHR) through Global Alliance for Chronic Diseases (GACD) aims to adapt and implement an evidence-based family centred approach (FCA) to prevent cardiovascular diseases (CVD) among adolescents and their families. This 5-year implementation science study will be conducted in 16 villages in Jinja district and another 16 in Kampala beginning April 2024 to evaluate the effectiveness of FCA in reducing the risk of CVD in Uganda and to assess feasibility, adoption, while measuring the costs of implementation. The study will be implemented by a group of researchers from MRC\u002FUVRI \\& LSHTM, University of British Columbia (Canada), TASO (Uganda) and University of California San Francisco (UCSF) - USA with guidance from the Ministry of Health - Uganda.",[29,30,31],"Adolescent Behavior","Lifestyle Modification","Cardiovascular Disease Other",[33,34,35,36,37,38,39],"cardiovascular risk","CVD","Ideal cardiovascular health","physical activity diary","food diary","diet diary","family centered","RECRUITING","2025-12-04",{"date":43,"type":44},"2025-12-12","ACTUAL",{"date":46,"type":44},"2025-07-05",{"date":48,"type":23},"2028-01",{"name":50,"class":51},"MRC\u002FUVRI and LSHTM Uganda Research Unit","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100526357","phase-3-implementing-oral-event-driven-and-daily-and-long-acting-pre-exposure-prophylaxis-in-mobile-men-in-sub-saharan-africa-100526357","NCT06133686","Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa","Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa: a Phase 3b, Open-label, Hybrid Type 2 Implementation and Effectiveness Trial","MOBILEMEN","Inclusion Criteria:\n\n1. Able and willing to provide informed consent\n2. Aged 18 years and above on the day of screening\n3. Willing to have a HIV test and receive the test results\n4. Male at birth\n5. In the past 6-months has travelled for work or to find work and spent at least one night away from home for work related purposes.\n6. Available for follow up for the duration of the study\n\nExclusion Criteria:\n\n1. Known HIV infection\n2. Confirmed HIV-positive test result, indeterminate HIV test result, and\u002For signs and symptoms of an acute HIV infection\n3. Body weight less than 35Kg at baseline\n4. Allergy to any of the study products\n5. Medical, social or other condition that, in the opinion of the site investigator, would interfere with the conduct of the study or safety of the participant (e.g., provided by self-report, or found upon medical history and examination or in available medical records)\n6. Use of contraindicated medications: Medication for tuberculosis (Rifampin, rifapentine) or anticonvulsants (Carbamazepine, oxcarbazepine, phenobarbital, phenytoin)\n7. Other reasons at the discretion of site investigator for unsuitability for study inclusion","MALE","18 Years","60 Years",{"count":64,"type":23},400,[66],"PHASE3","Title: Implementing oral (event-driven and daily) and long-acting Pre-exposure prophylaxis (PrEP) in mobile men in Sub-Saharan Africa\n\nDesign: A mixed method, multi-setting, multi-country, phase 3b, open-label, hybrid type 2 implementation and effectiveness randomized controlled trial (RCT). The trial will be carried out in 400 HIV negative men aged 18+ years in South Africa and Uganda. Men will be randomized 1:1 to either Group A: oral Tenofovir disoproxil fumarate\u002Femtricitabine (TDF-FTC) PrEP (event-driven or daily) or Group B: Long-acting injectable cabotegravir (CAB-LA) over 9-months. After 9-months participants from both groups will be offered choice of PrEP (oral TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Various strategies to support PrEP adoption, initiation, and persistence will be implemented, monitored, and reported on using a RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) implementation science framework.\n\nTreatment: CAB-LA or oral TDF-FTC Duration: 18 months",[69],"HIV",[71,69,72,73,74],"Mobile Men","Pre-exposure prophylaxis","Truvada","Cabotegravir","NOT_YET_RECRUITING","2023-11-13",{"date":78,"type":44},"2023-11-15",{"date":80,"type":23},"2024-04-01",{"date":82,"type":23},"2027-04-01",{"name":50,"class":51},""]